<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573089</url>
  </required_header>
  <id_info>
    <org_study_id>17.02</org_study_id>
    <nct_id>NCT03573089</nct_id>
  </id_info>
  <brief_title>Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)</brief_title>
  <acronym>PHOSPHATE</acronym>
  <official_title>An Investigator-initiated, International, Multi-centre, Prospective, Randomized, Open-label, Parallel-group, Superiority, and Pragmatic Large Simple Trial (LST) to Determine Whether the Currently Recommended Strategy of Intensive Reduction of Serum Phosphate Concentration Towards the Normal Level Results in Significant Patient-centred Benefits in End-stage Kidney Disease (ESKD) Patients Receiving Dialysis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Applied Health Research Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cambridge Clinical Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Otago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate
      levels in the blood. However, the effect of lowering blood phosphate levels on important
      patient-centred outcomes has never been tested. This trial will evaluate whether compared to
      high levels, lowering blood phosphate levels would reduce death or major events due to heart
      disease, improve physical health, and be cost-effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperphosphataemia is highly prevalent in patients with end-stage kidney disease (ESKD) and
      associated with increased mortality risk. The Clinical Practice Guidelines suggest lowering
      elevated phosphate levels towards the normal range (level 2C suggestion). However, trial data
      demonstrating that treatments that lower serum phosphate will improve patient-centred
      outcomes are lacking.

      The primary objective is to test the hypothesis that compared to a liberal serum phosphate
      concentration target of 2.0 to 2.5 mmol/L, intensive lowering of serum phosphate towards the
      normal level (≤1.50 mmol/L) with phosphate binders reduces the risk of fatal or non-fatal
      major cardiovascular events in ESKD patients receiving dialysis. The secondary objectives are
      to test the hypothesis that intensive lowering of serum phosphate towards the normal level
      with phosphate binders would improve physical health, fatigue, health-related quality of
      life, patient satisfaction, and pruritus; and be cost-effective.

      In this pragmatic, multinational, randomised controlled large simple trial, a total of 3600
      adult ESKD patients receiving dialysis will be randomised either to intensive (≤1.50 mmol/L)
      or liberalized (2.0-2.5 mmol/L) serum phosphate target. The choice and dose of phosphate
      binders will be at the treating physician's discretion and local practice to achieve and
      maintain serum phosphate concentration within the required target range according to
      randomisation. The primary endpoint is the composite endpoint of cardiovascular death,
      non-fatal major cardiovascular or peripheral arterial events. The secondary outcome measures
      will be individual components of the primary composite endpoint, all-cause death, and
      utility-based quality of life EQ5D-5L.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to a composite endpoint of cardiovascular death or non-fatal major cardiovascular event</measure>
    <time_frame>5 years</time_frame>
    <description>Time to a composite endpoint of cardiovascular death, non-fatal myocardial infarction or coronary revascularization, stroke, or peripheral arterial event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to individual components of the primary composite endpoint,</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause death</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility-based quality of life EQ5D-5L</measure>
    <time_frame>5 years</time_frame>
    <description>EQ5D-5L will be used to assess patient self-reported quality of life measures.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Differences in the serum concentrations of phosphate, PTH, calcium, alkaline phosphatase and albumin</measure>
    <time_frame>Time Frame: 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phosphate-lowering medication usage</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Phosphate-lowering medication self-reported adherence</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients requiring parathyroidectomy</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients developing calciphylaxis</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>5 years</time_frame>
    <description>The Gastrointestinal Symptom Rating Scale (GSRS) is a 15-item instrument designed to assess the symptoms associated with common GI disorders. It has five subscales (reflux, diarrhea, constipation, abdominal pain and indigestion). Subscale scores range from 1-7 and higher scores represent higher symptom burden i.e. more discomfort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Itch/pruritus visual analog scale</measure>
    <time_frame>5 years</time_frame>
    <description>The Pruritis 5-D scale contains five domains: duration, degree, direction, disability and distribution. The scores of each of the five domains are achieved separately and then summed together to obtain a total 5-D score. 5-D scores can potentially range between 5 (no pruritus) and 25 (most severe pruritus).</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness analysis:</measure>
    <time_frame>5 years</time_frame>
    <description>Difference in the incremental cost per Quality Adjusted Life Years gained</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Liberal phosphate target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liberal serum phosphate target of 2.0 to 2.5 mmol/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive phosphate target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive serum phosphate target of ≤1.50 mmol/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liberal phosphate target</intervention_name>
    <description>All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.</description>
    <arm_group_label>Liberal phosphate target</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensive phosphate target</intervention_name>
    <description>This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.</description>
    <arm_group_label>Intensive phosphate target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥45 years, or Age ≥18 years with diabetes,

          2. ESKD on haemodialysis or peritoneal dialysis, for at least 3 months,

          3. Currently prescribed at least one phosphate-lowering medication at any dose

          4. Able to provide informed consent

        Exclusion Criteria:

          1. Elective kidney transplantation scheduled,

          2. Concomitant major illness / comorbidity that may result in death in the next 6 months
             in the view of the treating physician,

          3. Participation in an interventional study that is likely to affect serum phosphate
             concentration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil Badve</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Queensland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ron Wald</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Hiemstra</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ron Wald</last_name>
    <phone>+1 416-867-3703</phone>
    <email>WaldR@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Hiemstra</last_name>
    <phone>+44 1223 3 36817</phone>
    <email>tfh24@cam.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Prince Alfred Hosptial</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Snelling, Dr</last_name>
      <email>Paul.Snelling@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muralikrishna Komala, Dr</last_name>
      <email>Muralikrishna.GangadharanKomala@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Badve, A/Prof</last_name>
      <email>s.badve@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Saint Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emma O'Lone, Dr</last_name>
      <email>emma.olone@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Sydney Renal Service</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grahame Elder, A/Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wollongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hichaim Cheikh Hasan, Dr</last_name>
      <email>HichamIbrahim.CheikhHassan@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunshine Coast University Hospital</name>
      <address>
        <city>Birtinya</city>
        <state>Queensland</state>
        <zip>4575</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rathika Krishnasamy, A/Prof</last_name>
      <email>Rathika.Krishnasamy@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharad Ratanjee, Dr</last_name>
      <email>sharad.ratanjee@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4110</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Johnson, Prof</last_name>
      <email>David.Johnson2@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundaberg Hospital</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clyson Mutatiri, Dr</last_name>
      <email>Clyson.Mutatiri@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairns Hospital</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shyam Dheda, Dr</last_name>
      <email>Shyam.Dheda@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fraser Coast Renal Service</name>
      <address>
        <city>Hervey Bay</city>
        <state>Queensland</state>
        <zip>4655</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krishan Madhan, Dr</last_name>
      <email>Krishan.Madhan@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Hospital</name>
      <address>
        <city>Mackay</city>
        <state>Queensland</state>
        <zip>4740</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roy Cherian, Dr</last_name>
      <email>roy.cherian@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Logan Hospital</name>
      <address>
        <city>Meadowbrook</city>
        <state>Queensland</state>
        <zip>4131</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken-Soon Tan, Dr</last_name>
      <email>ken-soon.tan@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Siddarth Sharma, Dr</last_name>
      <email>Siddharth.Sharma@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toowoomba Hospital</name>
      <address>
        <city>Toowoomba</city>
        <state>Queensland</state>
        <zip>4350</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sridevi Govindarajulu, Dr</last_name>
      <email>Sridevi.Govindarajulu@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central and Northern Adelaide Renal and Transplant Service</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Phillip Clayton, Dr</last_name>
      <email>Phil@anzdata.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Bedford Park</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Milton, Dr</last_name>
      <email>caroline.milton@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Mount, Dr</last_name>
      <email>Peter.MOUNT@austin.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holly Hutton, Dr</last_name>
      <email>H.Hutton@alfred.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Ruderman, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Latrobe Regional Hospital</name>
      <address>
        <city>Traralgon</city>
        <state>Victoria</state>
        <zip>3844</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Solomon Menahem, Dr</last_name>
      <email>solomon.menahem@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suda Swaminathan, Dr</last_name>
      <email>suda.swaminathan@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hemant Kulkarni, Dr</last_name>
      <email>hemant.kulkarni@health.wa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Collins, Dr</last_name>
      <email>michael.collins@adhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David McGregor, Dr</last_name>
      <email>david.mcgregor@cdhb.health.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rob Walker, Prof</last_name>
      <email>rob.walker@otago.ac.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hawkes Bay Hospital</name>
      <address>
        <city>Hastings</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Mc Nally, Dr</last_name>
      <email>andrew.mcnally@hawkesbaydhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Otahuhu</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Hood, Dr</last_name>
      <email>chris.hood@middlemore.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sasjed Valappil, Dr</last_name>
      <email>Sajed.Valappil@waitematadhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Murray Leikia, Dr</last_name>
      <email>murray.leikis@ccdhb.org.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whangarei Hospital</name>
      <address>
        <city>Whangarei</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Waala Saweirs, Dr</last_name>
      <email>Walaa.Saweirs@northlanddhb.org.nz</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>http://aktn.org.au/</url>
    <description>Australasian Kidney Trials Network Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal dialysis</keyword>
  <keyword>Randomised controlled trial</keyword>
  <keyword>Bone markers</keyword>
  <keyword>Cardiovascular risk factors</keyword>
  <keyword>Phosphate lowering agent</keyword>
  <keyword>End stage kidney disease</keyword>
  <keyword>Hyperphosphatemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the primary publication, after deidentification (text, tables, figures and appendices) will be available for individual participant data meta-analysis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 2 years and ending 5 years following main publication. Proposals may be submitted up to 5 years following article publication. After 5 years, the data will be available in our University's data warehouse but without investigator support other than deposited metadata.</ipd_time_frame>
    <ipd_access_criteria>An independent review board will assess proposals based on the following criteria: sound science, benefit-risk balancing and research team expertise.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

